Sources: - Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial (Published: 2025-12-11) - - American Association of Clinical Endocrinology Consensus Statement: Algorithm for the Evaluation and Treatment of Adults with Obesity/Adiposity-Based Chronic Disease - 2025 Update - PubMed (Published: 2025-01-01) - - Introduction and methodology: Standards of Care in Overweight and Obesity2025 | BMJ Open Diabetes Research & Care (Published: 2025-05-23) - #ObesityMedicine #WeightLoss #Retatrutide #TripleAgonist #GLP1 #ChronicDisease #HealthcareInnovation #Pharma #CardiovascularHealth #ObesityTreatment To view or add a comment, sign in Obesity, Metabolic Syndrome, and Osteoarthritis Require Integrative Understanding and Management by Mocanu, V., et al
Its unclear if the medication passes into breast milk or if it could affect a nursing baby, she explains
Blue nevus and "malignant blue nevus:" A concise review
Analyzing that example, the The study authors continued, We do not recommend changes in pharmacotherapy or SMBG frequency after vaccination because such changes would place an unnecessary burden on patients
Your chances at keeping excess weight off long-term increase when you implement lifestyle changes in nutrition and physical activity, in addition to semaglutide use
